Trials / Terminated
TerminatedNCT00116389
Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas
An Open-Label Phase 2 Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- Point Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the 6-month survival rate and safety of talabostat and gemcitabine in patients with stage IV adenocarcinoma of the pancreas.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | talabostat mesylate tablets | |
| DRUG | gemcitabine |
Timeline
- First posted
- 2005-06-29
- Last updated
- 2007-06-08
Locations
28 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00116389. Inclusion in this directory is not an endorsement.